Cardio-Oncology

A thorough understanding of onco-cardiology or cardio-oncology is essential for the effective treatment of cancer patients. Virtually all antineoplastic agents are related with cardiotoxicity. All patients who are being considered for chemotherapy, especially those who have prior history of cardiac disease should undergo detailed cardiovascular evaluation to optimize the treatment. Serial examination of left ventricular systolic function and cardiac biomarkers might also be considered in the selected populations of patient. Cardio-toxic effects of chemotherapy can be decreased by the frequent use of angiotensin-converting inhibitors of enzyme, angiotensin receptor blockers, or beta-blockers. Antiplatelet or anticoagulation therapy might be taken in patients with a potential hyper-coagulable state associated with chemotherapy or cancer. This Heart Congress scientific program has been CME and CPD certified.


  • Advanced cancer therapy
  • Heart malignancy
  • Intra-cardiac tumor
  • Cardiomyopathy
  • HER2-directed therapy
  • Vascular toxicities
  • Chemotherapy-related cardiac dysfunctions
  • Cardio-oncology programs

Related Conference of Cardio-Oncology

May 30-31, 2024

6th Euro Cardiology Congress

Vienna, Austria
May 30-31, 2024

39th World Congress on Heart Diseases

Vienna, Austria
June 20-21, 2024

5th European Summit on Cardiology Research

Dublin, Ireland
July 16-17, 2024

13th World Heart Congress

Paris, France
August 01-02, 2024

38th World Congress on Heart Diseases

Montreal, Canada
September 16-17, 2024

3rd Global Summit on Cardiology and Cardiac Surgery

Paris, France
October 24-25, 2024

11th International Conference on Interventional Cardiology

Zurich, Switzerland
October 30-31, 2024

7th Global Cardiovascular Research and Clinical Cardiology

Vancouver, Canada

Cardio-Oncology Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in